Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
BACKGROUND
Rifampicin (rifampin) has been reported to have drug-drug interaction with several 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors due to its ability to influence the function of cytochrome P450 enzymes or transporters. Rosuvastatin is absorbed from the blood into the liver by organic anion transporting polypeptide 1B1 and is then metabolized by cytochrome P450 isozyme 2C9.


OBJECTIVE
The aim of this study was to examine the effect of rifampicin on the pharmacokinetics of rosuvastatin.


METHODS
This was a randomized, single-blind, placebo-controlled, crossover study, with a 4-week washout period. Healthy male volunteers were treated for 6 days with rifampicin 450 mg or placebo once daily. On days 0 and 7, a single oral dose of rosuvastatin 20 mg was administered. Plasma concentrations of rosuvastatin were measured by liquid chromatography-tandem mass spectrometry.


RESULTS
A total of 18 healthy Chinese male volunteers (mean [SD] age, 21 [2] years; weight, 62 [7] kg; and body mass index was within the normal range [22.0-24.0 kg/m2]) were included in the study. The plasma concentrations of rosuvastatin were not significantly changed by pretreatment with rifampicin, although there was considerable interindividual variation in the plasma concentration of rosuvastatin. During the rifampicin phase, the AUC(0-infinity) of rosuvastatin decreased in 10 and increased in 8 of the 18 subjects. In 3 of the 8 subjects, the AUC(0-infinity) of rosuvastatin during the rifampicin phase was > or = 50% compared with the placebo phase; and only 1 increased by more than double (183%). Of those in the decreased group (n = 10), the AUC(0-infinity) values were decreased by >50% in 3 subjects and were not decreased by >30% in the remaining 7 subjects. The mean AUC(0-infinity) of rosuvastatin was 95.8% (110.4 [41.4] vs 115.3 [30.9] ng/mL . h(-1)) of the corresponding value during the placebo phase (P = NS). There was no statistically significant difference in either C(max) or t(1/2) of rosuvastatin between the rifampicin-treated and placebo groups (18.5 [6.3] vs 16.5 [5.5] ng/mL; 12.8 [3.0] vs 13.3 [2.8] h). The oral clearance of rosuvastatin was not significantly affected by rifampicin pretreatment either (0.4 [0.3] vs 0.3 [0.2] L . h; P = 0.072).


CONCLUSIONS
The pharmacokinetics of rosuvastatin were not significantly changed by coadministration of rifampicin in this small group of healthy male volunteers.
Zhang
Wei
W
Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China.
Deng
Sheng
S
Chen
Xiao-Ping
XP
Zhou
Gan
G
Xie
Hai-Tang
HT
He
Fu-Yuan
FY
Cao
Dan
D
Li
Yuan-Jian
YJ
Zhou
Hong-Hao
HH
D000328:Adult; D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D018592:Cross-Over Studies; D004347:Drug Interactions; D005464:Fluorobenzenes / Q000493:pharmacokinetics*; D006801:Humans; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics*; D008297:Male; D011743:Pyrimidines / Q000493:pharmacokinetics*; D012293:Rifampin / Q000494:pharmacology*; D000068718:Rosuvastatin Calcium; D016037:Single-Blind Method; D013449:Sulfonamides / Q000493:pharmacokinetics*
D000904:Antibiotics, Antitubercular; D005464:Fluorobenzenes; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D012293:Rifampin